Oruka Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | $-0.18 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 25, 2024 | After market close | – | $-0.14 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 1, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Oct 18, 2023 | After market close | – | $-0.10 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 21, 2023 | After market close | – | $-0.10 | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 24, 2023 | After market close | – | $-0.09 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 24, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Oct 28, 2022 | After market close | – | $-0.16 | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 2, 2022 | After market close | – | $-0.22 | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 2, 2022 | After market close | – | – | – |
Press releases
Announcements Oruka Therapeutics filed with the SEC
PRESS RELEASE, DATED AUGUST 10, 2026
Results of operations · EX-99.1 to Form 8-K
EXCERPT FROM PRELIMINARY PROSPECTUS SUPPLEMENT DATED APRIL 27, 2026
Results of operations · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 27, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESENTATION, DATED APRIL 27, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 17, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 17, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 11, 2024
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 11, 2024
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, ISSUED ON SEPTEMBER 3, 2024
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
PRESS RELEASE, ISSUED ON AUGUST 26, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, ISSUED ON AUGUST 23, 2024
Shareholder vote results · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, ISSUED ON AUGUST 16, 2024
Other events · EX-99.1 to Form 8-K
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Overview April 2024 ©2024
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
ARCA biopharma, Inc. and Oruka Therapeutics, Inc.
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
ARCA biopharma Announces 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
ARCA biopharma Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
Other events · EX-99.1 to Form 8-K
ARCA biopharma Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Establishes Special Committee of the Board of Directors
Other events · EX-99.1 to Form 8-K
ARCA biopharma Reports Topline Results for ASPEN-COVID-19
Other events · EX-99.1 to Form 8-K
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K